Boehringer Ingelheim
For Healthcare Professionals
x

Registration Form

Required.

Information you provide when registering will be shared with the account owner and host and can be used and shared by them in accordance with their Terms and Privacy Policy.

This webinar is for Health Care Professionals only. Upon submitting this registration, I am confirming that I am a Health Care Professional.

Giotrif 20 mg 30mg 40mg
giotrif 5 years

Management of GIOTRIF® adverse events in the real world

23/01/2024 | Author: Boehringer Ingelheim

Document ID: PC-SG-102271

RELATED CONTENT

What is Afatinib (Giotrif®)?

Afatinib (Giotrif®) is an irreversible ErbB Family blocker approved in more than 70 countries. It is indicated for the treatment of patients with distinct types of epidermal growth factor receptor mutation-positive (EGFR M+) locally advanced or metastatic non-small cell lung cancer (NSCLC), and for the treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. It is an oral, once-daily, targeted therapy.[1]

*Afatinib is approved in more than 70 countries including the EU, Japan, Taiwan, and Canada under the brand name Giotrif®, in the US under the brand name Gilotrif® and in India under the brand name Xovoltib®.
 

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about Afatinib (Giotrif®)?

The side effects of Afatinib are predictable, generally manageable and reversible. In studies to date, drug-related adverse events (AEs) were largely related to the gastrointestinal tract (diarrhoea) and skin disorders (rash), which is in line with EGFR tyrosine kinase inhibition.[1-4] For further details, please refer to the Local Prescribing Information.

References:
  • [1]
     GIOTRIF® Summary of Product Characteristics 2018
  • [2]
     Sequist L et al. J Clin Oncol 2013;31(27)3327–34.
  • [3]
     Wu YL et al. Lancet Oncol 2014;15(2):213–22.
  • [4]
     Park K et al. Lancet Oncol 2016;17(5):577–89.